Century Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-9.6M | $-126.6M | $-136.7M | $-130.9M | $-95.8M | $-53.6M |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | $13.1M | $13.3M | $13.0M | $8.4M | $3.7M | $1.4M |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $6.8M | $12.7M | $14.6M | $10.7M | $4.7M | $876.0K |
| Net Cash from Operating Activities | $-103.9M | $-110.1M | $-88.3M | $14.1M | $-89.0M | $-41.3M |
| Investing Activities | ||||||
| Capital Expenditures | $848.0K | $154.0K | $13.7M | $30.6M | $45.0M | $9.8M |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $107.5M | $47.5M | $61.1M | $-13.1M | $-298.3M | $-22.8M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $173.0K | $74.6M | $-9.7M | $27.2M | $417.8M | $47.7M |
| Net Change in Cash | — | — | — | — | — | — |
| Free Cash Flow | $-104.7M | $-110.3M | $-102.1M | $-16.6M | $-134.0M | $-51.1M |